Delaware
|
000-51481
|
13-3986004
|
(State or Other
|
(Commission File Number)
|
(I.R.S. Employer
|
Jurisdiction of Incorporation)
|
Identification No.)
|
|
5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
|
19044
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
SSKN
|
The NASDAQ Stock Market LLC
|
|
|
Exhibits.
|
|
|
|
|
|
|
|
Exhibit Number
|
Description
|
|
|
|
|
|
|
99.1
|
STRATA Skin Sciences Press Release dated November 2, 2020
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
Date: November 2, 2020
|
By:
|
/s/ Matthew C. Hill
|
|
|
|
Matthew C. Hill
|
|
|
|
Chief Financial Officer
|
|
•
|
Clinical Effectiveness – XTRAC produces excellent clinical outcomes with superior PASI 75 reduction in a high percentage (92% for XTRAC OTD) of
patients.
|
•
|
Speed of Response to Treatment – XTRAC excimer laser and the XTRAC MMD diagnostic tip achieve visible results within 5-7 weeks as compared to
systemics and biologics that require 3 months.
|
•
|
Adverse Events – Treatment with XTRAC technology is shown to be the safest of all modalities for plaque psoriasis. Adverse events are mild,
temporary, localized, and well tolerated.
|
•
|
Cost-Effectiveness of the XTRAC Technology – Among patients with moderate-to-severe psoriasis, the XTRAC excimer laser and XTRAC MMD diagnostic
tip produce clinical outcomes (an end point of PASI 75) that are comparable to biologics at just 3% of the cost.
|
•
|
Time Spent by Patients in Treatment - Actual treatment days per year for the XTRAC excimer laser used in conjunction with the MMD accessory
(18) and XTRAC (39) are significantly less than most other modalities: Etanercept (70 days), Methotrexate (62 days), NB-UVB (80 days) and, topicals (294 days), resulting in higher convenience and significantly lower patient frustration.
|
•
|
Remission Without Maintenance Therapy – XTRAC is the only treatment modality where patients can achieve 2.5 - 6 months of disease remission
without the need of a maintenance therapy, providing more enjoyable treatment free days.
|
Matthew Hill, Chief Financial Officer
|
||
STRATA Skin Sciences, Inc.
|
||
215-619-3200
|
||
ir@strataskin.com
|